Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report
Cervical cancer (CC) is the second most commonly diagnosed cancer and the third leading cause of cancer death among females. The options of treatment for recurrent/advanced CC are limited and patients experiencing recurrence after first line platinum-based chemotherapy have a poor prognosis. In this...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303893/full |
| _version_ | 1827585975682859008 |
|---|---|
| author | Anna Passarelli Carmela Pisano Elisabetta Coppola Jole Ventriglia Sabrina Chiara Cecere Marilena Di Napoli Luciano Carideo Secondo Lastoria Sandro Pignata |
| author_facet | Anna Passarelli Carmela Pisano Elisabetta Coppola Jole Ventriglia Sabrina Chiara Cecere Marilena Di Napoli Luciano Carideo Secondo Lastoria Sandro Pignata |
| author_sort | Anna Passarelli |
| collection | DOAJ |
| description | Cervical cancer (CC) is the second most commonly diagnosed cancer and the third leading cause of cancer death among females. The options of treatment for recurrent/advanced CC are limited and patients experiencing recurrence after first line platinum-based chemotherapy have a poor prognosis. In this context, immune checkpoint inhibitors (ICI)s antagonizing PD-1 and programmed death-ligand 1 (PD-L1) have profoundly changed the treatment scenario and outcomes in CC in the first or subsequent lines both as monotherapies or in combination with chemotherapy or other ICIs. Herein, we report the clinical case of a 74-year-old woman with metastatic CC with negative tumor PD-L1 expression who having disease progression after first-line of systemic treatment with platinum, thus undergoing to anti-PD-1 namely cemiplimab. The patient achieved a surprising, fast and complete metabolic response to cemiplimab immediately discontinued after only two cycles due to the onset of rare and severe immune-related adverse events (irAE)s such cardiovascular toxicity and hypertransaminasemia. Despite this, thirteen months later, the patient remains disease-free despite cemiplimab was withdrawn. |
| first_indexed | 2024-03-08T23:54:23Z |
| format | Article |
| id | doaj.art-13637c934c6e47e7b047a0176efec119 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T23:54:23Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-13637c934c6e47e7b047a0176efec1192023-12-13T05:41:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-12-011410.3389/fimmu.2023.13038931303893Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case reportAnna Passarelli0Carmela Pisano1Elisabetta Coppola2Jole Ventriglia3Sabrina Chiara Cecere4Marilena Di Napoli5Luciano Carideo6Secondo Lastoria7Sandro Pignata8Department of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Naples, ItalyDepartment of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Naples, ItalyDepartment of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Naples, ItalyDepartment of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Naples, ItalyDepartment of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Naples, ItalyDepartment of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Naples, ItalyNuclear Medicine Unit, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Naples, ItalyNuclear Medicine Unit, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Naples, ItalyDepartment of Urology and Gynecology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Fondazione G. Pascale, Naples, ItalyCervical cancer (CC) is the second most commonly diagnosed cancer and the third leading cause of cancer death among females. The options of treatment for recurrent/advanced CC are limited and patients experiencing recurrence after first line platinum-based chemotherapy have a poor prognosis. In this context, immune checkpoint inhibitors (ICI)s antagonizing PD-1 and programmed death-ligand 1 (PD-L1) have profoundly changed the treatment scenario and outcomes in CC in the first or subsequent lines both as monotherapies or in combination with chemotherapy or other ICIs. Herein, we report the clinical case of a 74-year-old woman with metastatic CC with negative tumor PD-L1 expression who having disease progression after first-line of systemic treatment with platinum, thus undergoing to anti-PD-1 namely cemiplimab. The patient achieved a surprising, fast and complete metabolic response to cemiplimab immediately discontinued after only two cycles due to the onset of rare and severe immune-related adverse events (irAE)s such cardiovascular toxicity and hypertransaminasemia. Despite this, thirteen months later, the patient remains disease-free despite cemiplimab was withdrawn.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303893/fullcemiplimabimmunotherapycervical cancerimmune-related adverse eventscardiotoxicityhepatotoxicity |
| spellingShingle | Anna Passarelli Carmela Pisano Elisabetta Coppola Jole Ventriglia Sabrina Chiara Cecere Marilena Di Napoli Luciano Carideo Secondo Lastoria Sandro Pignata Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report Frontiers in Immunology cemiplimab immunotherapy cervical cancer immune-related adverse events cardiotoxicity hepatotoxicity |
| title | Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report |
| title_full | Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report |
| title_fullStr | Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report |
| title_full_unstemmed | Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report |
| title_short | Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report |
| title_sort | complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer a case report |
| topic | cemiplimab immunotherapy cervical cancer immune-related adverse events cardiotoxicity hepatotoxicity |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303893/full |
| work_keys_str_mv | AT annapassarelli completeandearlyresponsetocemiplimabassociatedtosevereimmunetoxicityinadvancedcervicalcanceracasereport AT carmelapisano completeandearlyresponsetocemiplimabassociatedtosevereimmunetoxicityinadvancedcervicalcanceracasereport AT elisabettacoppola completeandearlyresponsetocemiplimabassociatedtosevereimmunetoxicityinadvancedcervicalcanceracasereport AT joleventriglia completeandearlyresponsetocemiplimabassociatedtosevereimmunetoxicityinadvancedcervicalcanceracasereport AT sabrinachiaracecere completeandearlyresponsetocemiplimabassociatedtosevereimmunetoxicityinadvancedcervicalcanceracasereport AT marilenadinapoli completeandearlyresponsetocemiplimabassociatedtosevereimmunetoxicityinadvancedcervicalcanceracasereport AT lucianocarideo completeandearlyresponsetocemiplimabassociatedtosevereimmunetoxicityinadvancedcervicalcanceracasereport AT secondolastoria completeandearlyresponsetocemiplimabassociatedtosevereimmunetoxicityinadvancedcervicalcanceracasereport AT sandropignata completeandearlyresponsetocemiplimabassociatedtosevereimmunetoxicityinadvancedcervicalcanceracasereport |